Literature DB >> 19932582

Pharmacologic concentrations of ascorbic acid cause diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines.

Zu-Yau Lin1, Wan-Long Chuang.   

Abstract

This study was to investigate whether ascorbic acid (AA) at pharmacologic concentration became prooxidant and had the potential to influence the expressions of angiogenic and angiostatic chemokine genes in hepatocellular carcinoma (HCC) cell lines. Influence of low (1 mM) and high (30 mM) pharmacologic concentrations of AA on two HCC cell lines (cell line A, HCC24/KMUH; cell line B, HCC38/KMUH) were studied by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Three angiogenic genes (CCL2, CXCL6, IL8), one angiostatic gene (CXCL10) and two genes related to oxidative stress (SOD2, VNN3) were selected for quantitative RT-PCR study. Both low and high pharmacologic concentrations of AA up-regulated CCL2, CXCL6, IL8, SOD2 and VNN3 genes in cell line A, but down-regulated CCL2 and IL8 genes in cell line B. CXCL6 gene in cell line B was down-regulated by high pharmacologic concentration of AA. CXCL10 gene was up-regulated by low pharmacologic concentration of AA, but was down-regulated by high pharmacologic concentration of AA in both cell lines. Low pharmacologic concentration of AA up-regulated VNN3 gene and high pharmacologic concentration of AA up-regulated SOD2 gene in cell line B. These results indicate that pharmacologic concentration of AA becomes prooxidant to HCC cells and has diverse influence on differential expressions of angiogenic chemokine genes in different HCC cell lines. Differential expressions of CXCL10 gene are determined by the concentrations of AA used. Clinical application of AA in patients with HCC should consider these effects. 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19932582     DOI: 10.1016/j.biopha.2009.06.005

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

Review 1.  Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics.

Authors:  Nermi L Parrow; Jonathan A Leshin; Mark Levine
Journal:  Antioxid Redox Signal       Date:  2013-06-19       Impact factor: 8.401

2.  Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer.

Authors:  Michael Graham Espey; Ping Chen; Brian Chalmers; Jeanne Drisko; Andrew Y Sun; Mark Levine; Qi Chen
Journal:  Free Radic Biol Med       Date:  2011-03-12       Impact factor: 7.376

3.  Plasma vascular non-inflammatory molecule 3 is associated with gastrointestinal acute graft-versus-host disease in mice.

Authors:  Na Wang; Xiaoyi Qin; Yigeng Cao; Bin Liang; Kang Yu; Haige Ye
Journal:  J Inflamm (Lond)       Date:  2018-01-05       Impact factor: 4.981

4.  Ascorbyl palmitate-incorporated paclitaxel-loaded composite nanoparticles for synergistic anti-tumoral therapy.

Authors:  Min Zhou; Xin Li; Yuanyuan Li; Qiu'e Yao; Yue Ming; Ziwei Li; Laichun Lu; Sanjun Shi
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 5.  Evidence-based complementary treatment of pancreatic cancer: a review of adjunct therapies including paricalcitol, hydroxychloroquine, intravenous vitamin C, statins, metformin, curcumin, and aspirin.

Authors:  Stephen Bigelsen
Journal:  Cancer Manag Res       Date:  2018-07-13       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.